Roivant Sciences Ltd. reported $7.5M of revenue over the trailing twelve months, −68% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $7.5M (to Q1 2026). Net income: −$266M, trailing twelve months to Q1 2026. Free cash flow: −$831M, trailing twelve months to Q1 2026. Operating margin: −11341%, trailing twelve months to Q1 2026.

ROIVRoivant Sciences Ltd.

Healthcare

$35.42+136% 1Y

$35.42

$14.7052 weeks$41.81

ROIV as reported

Roivant Sciences Ltd. reported $7.5M of revenue over the trailing twelve months, −68% on the year before. 9 reported series are charted on this page, each one as filed.

$7.5M

Revenue, trailing twelve months · to Q1 2026 · −68% against the twelve months before

Net income: −$266M
Net income · −46% year on year · trailing twelve months to Q1 2026
Free cash flow: −$831M
Free cash flow · −3.2% year on year · trailing twelve months to Q1 2026
Operating margin: −11341%
Operating margin · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for ROIV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$7.5M	−68%	Q1 2026
Net income	−$266M	−46%	Q1 2026
EPS	−$0.47	−33%	Q1 2026
Operating margin	−11341%	n/a	Q1 2026
Net margin	−5417%	n/a	Q1 2026
ROE	−10%	n/a	Q1 2026
ROA	−8.3%	n/a	Q1 2026
ROIC	129%	n/a	Q1 2024 · 8 quarters behind
Free cash flow	−$831M	−3.2%	Q1 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.